Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." ...

The move bolsters Merck’s lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

Merck is expanding its pipeline and portfolio of cardio-pulmonary disease treatments by acquiring Verona Pharma plc.

The purchase gives Merck Verona's Ohtuvayre inhaler to treat COPD Key Takeaways. Merck is paying about $10 billion for Verona ...

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's ...

Global markets have been seesawing this week, as traders digest the latest trade tariff news. Overnight, Asia-Pacific markets ...

Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...

Merck agreed to buy respiratory drugmaker Verona Pharma for about $10 billion as it tries to make up for huge expected patent ...